Your browser is no longer supported. Please, upgrade your browser.
Inovio Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-1.35 Insider Own1.10% Shs Outstand204.55M Perf Week-21.84%
Market Cap2.47B Forward P/E- EPS next Y-0.62 Insider Trans-12.66% Shs Float166.76M Perf Month23.56%
Income-179.70M PEG- EPS next Q-0.22 Inst Own33.70% Short Float25.84% Perf Quarter13.95%
Sales2.10M P/S1178.18 EPS this Y-15.40% Inst Trans2.79% Short Ratio2.70 Perf Half Y-1.88%
Book/sh1.96 P/B6.13 EPS next Y47.00% ROA-52.70% Target Price15.13 Perf Year221.55%
Cash/sh1.64 P/C7.34 EPS next 5Y0.00% ROE-103.00% 52W Range3.60 - 33.79 Perf YTD35.71%
Dividend- P/FCF- EPS past 5Y-14.60% ROI-137.90% 52W High-63.63% Beta1.00
Dividend %- Quick Ratio9.10 Sales past 5Y-17.00% Gross Margin- 52W Low241.39% ATR1.59
Employees190 Current Ratio9.10 Sales Q/Q-77.80% Oper. Margin- RSI (14)48.74 Volatility8.30% 14.67%
OptionableYes Debt/Eq0.17 EPS Q/Q147.10% Profit Margin- Rel Volume1.17 Prev Close12.01
ShortableYes LT Debt/Eq0.17 EarningsMar 01 AMC Payout- Avg Volume15.97M Price12.29
Recom2.70 SMA20-8.83% SMA509.32% SMA200-12.75% Volume4,028,995 Change2.33%
Feb-12-21Initiated Oppenheimer Outperform $35
Nov-17-20Downgrade ROTH Capital Neutral → Sell
Nov-10-20Upgrade ROTH Capital Sell → Neutral $8
Sep-28-20Upgrade Maxim Group Hold → Buy $20
Sep-28-20Downgrade Cantor Fitzgerald Overweight → Neutral
Jul-01-20Downgrade ROTH Capital Neutral → Sell $11
Jul-01-20Downgrade Maxim Group Buy → Hold
Jun-29-20Downgrade H.C. Wainwright Buy → Neutral
Jun-26-20Downgrade Stifel Buy → Hold $19 → $24
May-21-20Initiated The Benchmark Company Buy $28
Apr-30-20Downgrade ROTH Capital Buy → Neutral $13
Mar-13-20Downgrade RBC Capital Mkts Outperform → Sector Perform
Mar-13-20Downgrade Piper Sandler Overweight → Neutral
Dec-19-19Initiated ROTH Capital Buy $13
Feb-15-18Reiterated Maxim Group Buy $12 → $8
Oct-18-17Initiated RBC Capital Mkts Outperform $11
Sep-06-17Initiated Citigroup Buy $10
Jun-08-17Upgrade Piper Jaffray Neutral → Overweight
May-24-17Reiterated Maxim Group Buy $10 → $12
Mar-16-17Upgrade Maxim Group Hold → Buy $10
Feb-24-21 01:45AM  
Feb-23-21 08:00AM  
Feb-21-21 06:26AM  
Feb-18-21 01:08PM  
Feb-16-21 08:00AM  
Feb-15-21 06:30AM  
Feb-12-21 12:02PM  
Feb-07-21 06:55AM  
Feb-03-21 04:22PM  
Feb-02-21 10:43AM  
Feb-01-21 04:17PM  
Jan-28-21 10:43AM  
Jan-25-21 04:01PM  
Jan-22-21 01:16AM  
Jan-21-21 09:18AM  
Jan-20-21 10:09PM  
Jan-06-21 09:15PM  
Jan-04-21 09:25AM  
Dec-30-20 07:02AM  
Dec-28-20 04:05PM  
Dec-25-20 07:54AM  
Dec-24-20 11:04AM  
Dec-23-20 10:20AM  
Dec-19-20 06:53AM  
Dec-17-20 08:51AM  
Dec-16-20 12:30AM  
Dec-15-20 09:52AM  
Dec-13-20 02:40PM  
Dec-11-20 06:45AM  
Dec-10-20 08:00AM  
Dec-09-20 08:51PM  
Dec-07-20 09:23AM  
Dec-04-20 10:01AM  
Dec-03-20 05:53PM  
Dec-02-20 07:04AM  
Dec-01-20 07:00AM  
Nov-30-20 01:56PM  
Nov-27-20 11:23AM  
Nov-24-20 07:03AM  
Nov-23-20 08:00AM  
Nov-20-20 03:56PM  
Nov-19-20 08:21PM  
Nov-17-20 05:41PM  
Nov-16-20 04:42PM  
Nov-15-20 06:14AM  
Nov-14-20 09:27AM  
Nov-12-20 08:35AM  
Nov-11-20 04:57PM  
Nov-10-20 06:08AM  
Nov-09-20 05:19PM  
Nov-08-20 07:12AM  
Nov-07-20 06:55AM  
Nov-06-20 10:20AM  
Nov-04-20 06:25AM  
Nov-03-20 09:00AM  
Oct-31-20 05:51AM  
Oct-29-20 10:41AM  
Oct-28-20 11:58AM  
Oct-27-20 06:57PM  
Oct-26-20 08:00AM  
Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat, cure, and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its SynCon immunotherapy design has the ability to break the immune system's tolerance of cancerous cells and facilitate cross-strain protection against unmatched and matched pathogens. The company is involved in conducting and planning clinical studies of its DNA medicines for HPV-associated precancers, including cervical, vulvar, and anal dysplasia; HPV-associated cancers, including head and neck, cervical, anal, penile, vulvar, and vaginal; other HPV-associated disorders, such as recurrent respiratory papillomatosis; glioblastoma multiforme; prostate cancer; HIV; Ebola; Middle East Respiratory Syndrome (MERS); Lassa fever; Zika virus; and the COVID-19 virus (coronavirus). Its partners and collaborators include ApolloBio Corp., AstraZeneca PLC or AstraZeneca, Beijing Advaccine Biotechnology Co., The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations (CEPI), Defense Advanced Research Projects Agency (DARPA), GeneOne Life Science, HIV Vaccines Trial Network, the U.S. Defense Threat Reduction Agency's Medical CBRN Defense Consortium (MCDC), National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Plumbline Life Sciences, Regeneron Pharmaceuticals, Roche/Genentech, the University of Pennsylvania, the Walter Reed Army Institute of Research, and The Wistar Institute. The company also has an agreement with Richter-Helm BioLogics GmbH & Co. KG to support investigational DNA vaccine INO-4800, which is currently in Phase I clinical testing for COVID-19; and a partnership with International Vaccine Institute and Seoul National University Hospital. The company was founded in 1979 and is headquartered in Plymouth Meeting, Pennsylvania.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BENITO SIMON XDirectorFeb 16Option Exercise3.562,0007,12053,650Feb 18 07:04 PM
BENITO SIMON XDirectorFeb 16Sale14.682,00029,36051,650Feb 18 07:04 PM
Kim Jong JosephChief Executive OfficerFeb 03Option Exercise4.5662,500285,0001,140,813Feb 03 07:14 PM
Kim Jong JosephChief Executive OfficerFeb 03Sale14.2462,500890,0001,078,313Feb 03 07:14 PM
Shea Jacqueline ElizabethChief Operating OfficerFeb 01Option Exercise3.6222,37681,00166,871Feb 03 07:12 PM
Kim Jong JosephChief Executive OfficerFeb 01Sale15.00100,0001,500,0001,078,313Feb 03 07:14 PM
Shea Jacqueline ElizabethChief Operating OfficerFeb 01Sale15.0528,336426,38338,535Feb 03 07:12 PM
Shea Jacqueline ElizabethChief Operating OfficerJan 28Option Exercise3.6255,248199,99861,208Jan 29 07:03 PM
Shea Jacqueline ElizabethChief Operating OfficerJan 28Sale12.0416,713201,22544,495Jan 29 07:03 PM
Shea Jacqueline ElizabethChief Operating OfficerJan 27Option Exercise3.6222,37681,00134,296Jan 29 07:03 PM
Shea Jacqueline ElizabethChief Operating OfficerJan 27Sale12.0228,336340,4945,960Jan 29 07:03 PM
KIES PETERCFOJan 15Option Exercise4.5630,000136,800149,290Jan 15 07:25 PM
KIES PETERCFOJan 15Sale10.0230,000300,558119,290Jan 15 07:25 PM
Zoth Lota S.DirectorJan 05Sale9.489619,11015,232Jan 05 04:09 PM
BENITO SIMON XDirectorJan 04Option Exercise3.562,7509,79054,400Jan 05 04:08 PM
BENITO SIMON XDirectorJan 04Sale9.002,75024,75051,650Jan 05 04:08 PM
Weiner David B.DirectorDec 15Option Exercise4.5617,50079,800844,719Dec 17 07:06 PM
KIES PETERCFODec 15Option Exercise2.2720,00045,300139,290Dec 17 07:07 PM
KIES PETERCFODec 15Sale10.6920,000213,706119,290Dec 17 07:07 PM
Weiner David B.DirectorDec 15Sale10.7117,500187,352827,219Dec 17 07:06 PM
Humeau LaurentChief Scientific OfficerNov 10Sale9.7519,466189,79424,500Nov 12 04:21 PM
Humeau LaurentChief Scientific OfficerAug 10Sale19.0619,467371,00443,966Aug 12 06:59 PM
Kim Jong JosephChief Executive OfficerJul 30Sale21.13100,0002,113,4501,188,313Jul 31 07:12 PM
KIES PETERCFOJul 15Option Exercise2.4035,00084,000154,290Jul 17 07:00 PM
KIES PETERCFOJul 15Sale24.9535,000873,208119,290Jul 17 07:00 PM
KIES PETERCFOJun 30Sale26.5035,000927,500119,290Jul 02 09:05 PM
Humeau LaurentChief Scientific OfficerJun 22Sale14.7019,467286,16563,433Jun 24 04:56 PM
BENITO SIMON XDirectorMay 20Option Exercise4.608,75040,25060,400May 20 05:37 PM
BENITO SIMON XDirectorMay 20Sale15.958,750139,59451,650May 20 05:37 PM
Weiner David B.DirectorMay 11Sale11.842,40428,463827,219May 12 04:26 PM
Weiner David B.DirectorMar 12Sale11.143,50038,990821,610Mar 12 04:40 PM
Weiner David B.DirectorMar 10Sale9.323,50032,620825,110Mar 12 04:40 PM
Weiner David B.DirectorMar 09Sale18.003,50063,000816,944Mar 09 04:20 PM